Int J Impot Res:缺血性阴茎异常勃起治疗实践

2019-02-19 AlexYang MedSci原创

阴茎分流非外科手术干预治疗缺血性阴茎勃起功能障碍(IPR)中是标准的医疗方法。由于阳痿率高、体纤维化和阴茎长度减少发生率高。最近的文献指出这些患者可以从直接的阴茎假体移植(PP)中受益。最近,有研究人员评估了当前IPR治疗的实践模式,并且调查了直接的PP移植在拖延较久的IPR(大于36小时)中的治疗效果。研究发现,调查的响应率为11.6%(n=251)。大多数的响应者为的泌尿科医师(173),来自

阴茎分流非外科手术干预治疗缺血性阴茎勃起功能障碍(IPR)中是标准的医疗方法。由于阳痿率高、体纤维化和阴茎长度减少发生率高。最近的文献指出这些患者可以从直接的阴茎假体移植(PP)中受益。

最近,有研究人员评估了当前IPR治疗的实践模式,并且调查了直接的PP移植在拖延较久的IPR(大于36小时)中的治疗效果。研究发现,调查的响应率为11.6%(n=251)。大多数的响应者为的泌尿科医师(173),来自美国的占比49.1%,并且完成了男性性医学、男性健康、重建或者男科学学习。大多数(91.3%)至少见过1个长时间阴茎勃起症(不小于36个小时)案例,并且需要每年进行外科手术治疗。另外,与分流术(小于40%,不小于10次)相比,研究人员还发现响应者具有在阴茎假体方面更加丰富的经验(大于70%,不小于10次)。总之,70.9%的响应者认为可塑的阴茎假体要比阴茎分流更加舒适。然而,阴茎分流仍旧是大约80%响应者的首先外科手术治疗方法,而只有12.7%的响应者认为首选PP。研究人员还发现不多于40%的响应者目前使用阴茎MRI或者活检来对拖延的时间进行评估。

最后,研究人员指出,他们是首次在全球范围内对IPR治疗的临床实践进行评估。与其他匿名的自我报道的调查类似,回忆和样本偏差均是内在的限制。IPR的阴茎分流仍旧是优先的选择,而响应者认为进行PP外科手术要比进行阴茎分流手术更加有信心。

原始出处:

Mohit Butaney, Nannan Thirumavalavan, Dayron Rodriguez et al. Current practice in the management of ischemic priapism: an anonymous survey of ISSM members. Int J Impot Res. 4 Feb 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893156, encodeId=7cd0189315678, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 14 10:02:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771169, encodeId=f2b81e71169f3, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Tue Nov 26 18:02:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293918, encodeId=bc04129391802, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575104, encodeId=b5a215e5104ee, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893156, encodeId=7cd0189315678, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 14 10:02:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771169, encodeId=f2b81e71169f3, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Tue Nov 26 18:02:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293918, encodeId=bc04129391802, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575104, encodeId=b5a215e5104ee, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-11-26 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893156, encodeId=7cd0189315678, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 14 10:02:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771169, encodeId=f2b81e71169f3, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Tue Nov 26 18:02:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293918, encodeId=bc04129391802, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575104, encodeId=b5a215e5104ee, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-21 dingxiaobo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893156, encodeId=7cd0189315678, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 14 10:02:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771169, encodeId=f2b81e71169f3, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Tue Nov 26 18:02:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293918, encodeId=bc04129391802, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575104, encodeId=b5a215e5104ee, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Feb 21 05:02:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-21 智慧医人

相关资讯

Int J Impot Res:吡格列酮对阴茎勃起功能保护作用可以通过抑制类胰岛素生长因子-1受体抑制消除

最近,有研究人员在神经挤压伤小鼠进行吡格列酮(Pio)治疗后,探究了是否类胰岛素生长因子-1(IGF-1)途径参与了阴茎勃起功能的改善。研究人员将 Sprague-Dawley大鼠分成了4个小组。第一组进行为Sham组(n=5)。第二组经历双边海绵体神经损伤(BCNI,N=7)。第三组进行BCNI和Pio治疗(BCNI+Pio, n=7),而第四组经历BCNI,外加Pio治疗和IGF-1抑制(BC

Int J Impot Res:达泊西汀/西地那非组合药片治疗早泄和伴随的阴茎勃起功能障碍效果的安全性研究

早泄(PE)和阴茎勃起功能障碍(ED)是男性瘤最常见的性功能障碍。ED通常见于具有PE的患者。尽管最近的指南推荐在PE和ED患者中首先治疗ED,该推荐并不是基于证据,并且关于达泊西汀/西地那非组合药片治疗这些患者的效果和安全性相关数据有限。最近,有研究人员评估了达泊西汀/西地那非组合药片在治疗PE以及伴随ED患者中的临床效果和安全性。他们的研究是一个单中心、单臂和开放标签临床研究,进行的时间为20

Int J Impot Res:2型糖尿病男性阴茎勃起功能障碍的流行度和相关性分析

最近,有研究人员在一个2型糖尿病男性样本群体中评估了阴茎勃起功能(ED)的流行度和相关性。研究包括了2016年10月和2017年4月之间,在研究人员所在糖尿病门诊治疗的2型糖尿病男性患者。这些参与者完成了一个国际阴茎勃起功能指数(IIEF-5)简短版本调查问卷,从而来诊断ED严重度等级。所有经历了阴茎功能排查的患者还经历了身体检查,并询问了人口和医疗历史。最后,总共包括了550名男性,排除了20名

Int J Impot Res:勃起和射精功能障碍糖尿病患者低剂量和高剂量他达拉非药物使用对比研究

最近,有研究人员比较了每日5mg和按需使用20mg他达拉非药物在具有勃起功能障碍(ED)糖尿病患者中使用情况,以及2中不同的用药剂量方式对射精和下尿道症状(LUTS)影响。研究包括了63名患有ED的糖尿病患者,其中31名每天使用5mg他达拉非,32名按需每个月进行4次的使用,每次20mg,共进行3个月。勃起功能、勃起硬度、射精功能和LUTS在治疗前、治疗第一个月和第三个月时进行评估。研究发现,2种

Int J Impot Res:慢性氏菌病患者阴茎勃起功能障碍研究

到目前为止,只有一个研究调查了慢性氏菌病患者阴茎勃起功能障碍(ED)情况,并且还没有包含对照组。最近,有研究人员在慢性氏菌病患者中确定了ED的流行度,并与正常参与者进行了比较,探索了ED的预测因子。研究包括了93名慢性氏菌病患者和92名正常参与者,时间为2013年6月到2017年8月。慢性氏菌病通过标准管凝集试验来进行诊断,具体是阳性免疫球蛋白G抗体滴度(≥1:160),且症状持续不小于1年。平均